Leflunomide
- 30 October 1996
- journal article
- new drug-profile
- Published by Springer Nature in Clinical Immunotherapeutics
- Vol. 6 (4) , 300-305
- https://doi.org/10.1007/bf03259090
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Blood Distribution and Single-Dose Pharmacokinetics of LeflunomideTherapeutic Drug Monitoring, 1995
- Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Newer immunosuppressive drugs and other agents for the treatment of rheumatoid arthritis - An updateExpert Opinion on Investigational Drugs, 1995
- Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?Inflammation Research, 1995
- Leflunomide interferes with pyrimidine nucleotide biosynthesisInflammation Research, 1995
- Measurement of the Active Leflunomide Metabolite (A77 1726) by Reverse-Phase High-Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1995
- Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritisInflammation Research, 1994
- Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomideFEBS Letters, 1993
- EVIDENCE THAT GENISTEIN, A PROTEIN-TYROSINE KINASE INHIBITOR, INHIBITS CD28 MONOCLONAL-ANTIBODY-STIMULATED HUMAN T CELL PROLIFERATIONTransplantation, 1991
- Disease modifying activity of HWA 486 in rat adjuvant-induced arthritisInflammation Research, 1987
- Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the ratInternational Journal of Immunopharmacology, 1985